Case Studies
range and an increased percentage of fetal hemoglobin (HbF). In patient with HbAS disease, the HbS is approximately 40%, HbA is approximately 60%, the HbA2 percentage is normal or slightly increased, and the HbF percentage is normal.
Because of demographic diversity, different ethnicities, and migration, we have observed a spectrum of the co-inheritance of a variety of mutations and deletions. 7 This article reports a novel co-inheritance of 3 α-thalassemia determinants (deletion, gene triplication, and point mutation) in a pregnant woman with sickle cell disease.
Material and Methods
This patient was referred by hematologists to the Prenatal diagnosis (PND) center of Shafa Hospital of the Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, with suspicion of α-thalassemia and sickle cell disease. After preliminary testing, results for complete blood cell count (CBC), hemoglobin electrophoresis (ie, acetate cellulose), and iron levels ruled out iron-deficiency anemia, genetic tests were conducted to identify and confirm the presence of thalassemia and/or hemoglobinopathies.
Venous blood was drawn from the patient and her husband and collected in an ethylenediamineteraacetic acid (EDTA) tube for hematologic parameters determination (Sysmex K1000 Hematology Analyzer, Sysmex Corporation, Kobe, Japan) and Hb electrophoresis (cellulose acetate in alkaline pH of 8.6); also, an amniotic-fluid sample was withdrawn from the fetus. Samples for molecular DNA analysis were extracted using AccuPrep Genomic DNA Extraction Kit (Bioneer Corporation, Daejeon, South Korea).
αand β-globin genes were analyzed using a reverse dot-blot assay as instructed (ViennaLab Diagnostics Gmbh, Vienna, Austria). Briefly, in this method the normal and mutant sequences were amplified using biotinylated primer sets by polymerase chain reaction (PCR), then hybridized to fixed probes on a nitrocellulose strip and finally, visualized by an enzymatic reaction benefiting from biotin-avidin affinity.
Using the blood-analysis kit, 21 deletions, various point mutations, and an α-gene triplication could be identified simultaneously. Separate gap PCRs for the 3 most frequent deletions (3.7, 4.2, and med) were performed 5 to verify the strip assay result. In cases in which the point mutation seen in the strip assay was present, α-globin genes were sequenced for further confirmation. The β-globin gene was primarily studied by direct sequencing; the amplification refractory mutation system (ARMS) and linkage analysis were used as secondary methods. 6 After detection of α-gene triplication by RNA-binding domain (RBD), the heterozygous status was checked by multiplex ligationdependent probe amplification (MLPA) genetic testing. 8 Further, for β-globin gene sequencing, the forward and reverse strands were both sequenced to confirm cd6 homozygosity. Written Informed consent was obtained from the patient involved in this study and her husband.
This study was approved by Ahvaz Jundishapur University of Medical Sciences ethics committee.
Case History
A 24-year-old pregnant woman, at 7 weeks' gestation, from Ahvaz, a city in the southwestern region of Iran, was sent to our hospital for fever, anemia, and arthralgia. The patient underwent PND assessment because of her thalassemia and her HbS background. Via genetic testing, she was found to have a -α3.7 deletion, anti-3.7 gene triplication, and α-gene point mutation HBA2: c.*94A>G ( Figure 1) . In β-globin gene studies, the patient was shown to have the HBB: c.20A>T, Glu6Val mutation in homozygous form ( Figure  2 ). Finally, the fetus (proband) was found to have a single (-α3.7) and a double (--MED) deletion on the α gene, which was concomitant with heterozygous HBB: c.20A>T, Glu6Val mutation.
Family Study
The hematological data, clinical manifestation, and result of hemoglobin analysis of the parents are summarized in Table 1 . The patient's husband was 26 years old and a carrier of α-thalassemia ( Table 1) . The mother tested homozygous for HbS (ie, she does not have sickle cell trait) and appeared to have no symptoms of sickle cell anemia. Her α-globin mutation may modify her risk for symptoms of sickle cell disease but these factors shouldn't put her at risk for significant thalassemia symptoms. However, the fetus, at 7 weeks' 
Discussion
Herein, we report the case of a patient with an infrequent hereditary arrangement of 4 various genetic anomalies of hemoglobin genes: the patient and her husband had 3 mutations on the α-gene and a sickle-cell anomaly on the β-gene, which is a rare combination. 9, 10 The co-occurrence of sickle-cell anemia with α-thalassemia (due to the 3.7 kb deletion) is extremely common in ethnic African populations. What makes this case potentially unique is that the unusual α-globin point mutation and triplication in the mother is typically seen in patients of Asian ethnic origin. The mother's c.*94A>G (a2PA6) mutation is presumably located on the same chromosome as the triplication, which had previously been reported 11 in association with an α-globin triplication. The mutation in the present case, which was comprised of the combination of c.*94A>G/triplication and the 3.7 kb deletion, might mean that the patient has a more significant level of α-thalassemia than most individuals with reported sickle cell disease and α-thalassemia.
Sickle cell disease is itself quite variable; factors such as genetic and environmental influences contribute to this variability. One of the most important genetic factors is thalassemia.
Individuals with sickle cell trait are heterozygous for HbS; therefore, they have a 50% chance of transmitting the mutation to their son or daughter. For children to develop sickle cell disease, both of their parents almost always must carry a mutation. The risk of transmitting α-thalassemia depends on the nature of the mutation.
As can be observed from the data in this report, this case is a classic example of moderately severe sickle α-thalassemia disease. Thalassemia is very common among people of Mediterranean ethnic origin. The sickle cell gene also exists more commonly in people of the same ethnic origin. In the United States, 10% of the population is at risk of sickle cell anemia; in northwestern Europe, between 2% and 9% are at risk for hemoglobin disorders. In some Southeast Asian countries, as much as 40% of the population may carry significant hemoglobin mutations, resulting in increased rates of infants born with thalassemia. 12 Hemoglobin analyses of the parents of such infants have shown that the fraction of HbS was extremely high, namely, 94.7% in the mother, whereas the MCV was decreased in both parents to less than 71 fl.
The complete or partial deletion of both α-genes in cis deletion results in no α-chain synthesis; hence, rare deletions that cause α 0 -thalassaemia remove the regulatory region, which lies 40 to 50 kb upstream of the α-globin gene cluster, leaving the α-genes intact. Moreover, the coexistence of the anti-3.7 gene triplication at a point mutation in cis deletion is a rare entity that is observed in our case individual.
Patients with HbH disease have only a single active α-globin gene and manifest moderate to severe anemia. Deletion of all 4 α-globin genes (--/--), has the most severe manifestation, known as Hb Bart's hydrops fetalis syndrome, which is generally associated with death in utero. 2 The consequences of α-thalassemia on sickle-cell anemia are possibly connected to an essential effect on mean corpuscular hemoglobin concentration (MCHC) and polymerization; further, simultaneous effects on other properties of sickle cells and the possibility that the MCHC differences may be secondary to sickling effects cannot be overlooked. Studies of the phenotypic results of the interaction of α-thalassemia and sickle-cell anemia will provide further insight into the causes of clinical diversity in sickle cell disease. 13 Co-existing α-thalassemia and sickle cell disease significantly improved hematological parameters and resulted in fewer blood transfusions, 14 may cause musculoskeletal pain, 15 and decreases the risk of cerebrovascular disease in children with sickle cell anemia. 16, 17 In conclusion, we report an extremely rare combination of α-globin gene disease and sickle cell trait. This combination may explain the mild form of thalassemia disease that manifests with moderate anemia. LM
